Régie de l'Assurance Maladie du Québec Adds Aegerion Pharmaceuticals Capsules to Formulary

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has announced that the Régie de l’Assurance Maladie du Québec (RAMQ) has added JUXTAPID™ (lomitapide) capsules to its formulary. This decision is effective November 20, 2015.
According to the press release:

The listing was based on a recommendation from l’Institut National d’Excellence en Santé et en Services Sociaux (INESSS) and is subject to a Listing Agreement between the Quebec Minister of Health and Social Services and Aegerion Pharmaceuticals (Canada) Ltd.  The Listing Agreement is based on Aegerion’s price for JUXTAPID in Canada, which is a fixed daily cost irrespective of the dose prescribed and strengths dispensed.
“We are pleased with decision of the RAMQ to add JUXTAPID to its formulary, furthering Aegerion’s goal of increasing access to our medicines for adult HoFH patients in need,” said Sandford D. Smith, Chief Executive Officer of Aegerion.
HoFH is a serious, rare genetic disease that impairs the function of the receptor responsible for removing LDL-cholesterol from the body, which results in extreme elevation of blood cholesterol levels. Patients with HoFH often develop premature and progressive atherosclerosis, a narrowing or blocking of the arteries.

Click here to read the full press release.